Publication
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerB-Cell Non-Hodgkin Lymphomacivic_curation1.00
- cancerDiffuse Large B-Cell Lymphomacivic_curation1.00
- drugTazemetostatcivic_curation1.00
- geneEZH2civic_curation1.00
- variantEZH2 A682Gcivic_curation1.00
- variantEZH2 A692Vcivic_curation1.00
- variantEZH2 Y646Ccivic_curation1.00
- variantEZH2 Y646Fcivic_curation1.00
- variantEZH2 Y646Hcivic_curation1.00
- variantEZH2 Y646Ncivic_curation1.00
- variantEZH2 Y646Scivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29650362
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EZH2 A682G + EZH2 A692V + EZH2 Y646C + EZH2 Y646F + EZH2 Y646H + EZH2 Y646N + EZH2 Y646S1 | ||||||||
| Tazemetostat | B-Cell Non-Hodgkin Lymphoma | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11220In a multicentre, open-label, phase 1 trial, tazemetostat was evaluated in 64 adult patients (≥18 years) with relapsed or refractory B-cell non-Hodgkin lymphoma (n=21) or advanced solid tumours (n=43)… (full text at CIViC) PMID 29650362 · Italiano et al., 2018 · Open in CIViC | civic |
| EZH2 Y646H1 | ||||||||
| Tazemetostat | Diffuse Large B-Cell LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID9377A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, inc… (full text at CIViC) PMID 29650362 · Italiano et al., 2018 · Open in CIViC | civic |
| SMARCA4 Underexpression1 | ||||||||
| Tazemetostat | Malignant NeoplasmALIAS | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID6373Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. One SMARCA4 n… (full text at CIViC) PMID 29650362 · Italiano et al., 2018 · Open in CIViC | civic |
| SMARCB1 Underexpression1 | ||||||||
| Tazemetostat | Malignant NeoplasmALIAS | Predictive | C | Supports Sensitivity Response | 3 | rejected | EID6374Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. One SMARCA4 n… (full text at CIViC) PMID 29650362 · Italiano et al., 2018 · Open in CIViC | civic |